The cellular delivery of antisense oligonucleotides and ribozymes

被引：86

作者：

Hughes, MD ^{[1
]}

Hussain, M

Nawaz, Q

Sayyed, P

Akhtar, S

机构：

[1] Aston Univ, Pharmaceut Sci Res Inst, ACGT, Birmingham B4 7ET, W Midlands, England

[2] Kuwait Univ, Fac Pharm, Safat 13110, Kuwait

来源：

DRUG DISCOVERY TODAY | 2001年 / 6卷 / 06期

基金：

英国生物技术与生命科学研究理事会; 英国医学研究理事会;

关键词：

D O I：

10.1016/S1359-6446(00)00326-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The design and development of antisense oligonucleotides and ribozymes for the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. Improvements in oligonucleotide chemistry have led to the synthesis of nucleic acids that are relatively stable in the biological milieu. However, advances in cellular targeting and intracellular delivery will probably lead to more widespread clinical applications. This review looks at recent advances in the in vitro and in vivo delivery of antisense oligodeoxynucleotides and ribozymes.

引用

页码：303 / 315

页数：13

共 113 条

[1] Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells [J].

Abe, T ;

Suzuki, S ;

Hatta, T ;

Takai, K ;

Yokota, T ;

Takaku, H .

ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1998, 9 (03) :253-262

[2] ABSORPTION, TISSUE DISTRIBUTION AND IN-VIVO STABILITY IN RATS OF A HYBRID ANTISENSE OLIGONUCLEOTIDE FOLLOWING ORAL-ADMINISTRATION [J].

AGRAWAL, S ;

ZHANG, XS ;

LU, ZH ;

ZHAO, H ;

TAMBURIN, JM ;

YAN, YM ;

CAI, HY ;

DIASIO, RB ;

HABUS, I ;

JIANG, ZW ;

IYER, RP ;

YU, D ;

ZHANG, RW .

BIOCHEMICAL PHARMACOLOGY, 1995, 50 (04) :571-576

[3] Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres [J].

Akhtar, S ;

Lewis, KJ .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 151 (01) :57-67

[4]

Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2

[5] Antisense technology: Selection and delivery of optimally acting antisense oligonucleotides [J].

Akhtar, S .

JOURNAL OF DRUG TARGETING, 1998, 5 (04) :225-234

[6] In vivo studies with antisense oligonucleotides [J].

Akhtar, S ;

Agrawal, S .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :12-18

[7] STABILITY OF ANTISENSE DNA OLIGODEOXYNUCLEOTIDE ANALOGS IN CELLULAR-EXTRACTS AND SERA [J].

AKHTAR, S ;

KOLE, R ;

JULIANO, RL .

LIFE SCIENCES, 1991, 49 (24) :1793-1801

[8] The delivery of antisense therapeutics [J].

Akhtar, S ;

Hughes, MD ;

Khan, A ;

Bibby, M ;

Hussain, M ;

Nawaz, Q ;

Double, J ;

Sayyed, P .

ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21

[9]

Alahari SK, 1996, MOL PHARMACOL, V50, P808

[10]

Arora V, 2000, J PHARMACOL EXP THER, V292, P921

← 1 2 3 4 5 6 7 8 9 10 →